Log in
Registration
Українська
English
Search for:
Home
Electronic publication
Fresh number
Archives
Authors
About Edition
Subscription
Requirements for authors
Reviewing
Editorial board
Organization of anticancer fight
Tumors of the chest cavity
Tumors of abdominal organs
Tumors of skin, soft tissues, bones
Breast tumor
Oncogynecology
Tumors of the head and neck
Oncurology
Oncohematology
Radiation diagnostics, radiation therapy
Experimental studies
Number Т. 10, № 3-4 (39-40)
Magazine online
Допомога хворим на COVID-19 на Львівщині
Еволюція SARS-CoV-2: нові докази ролі імунореактивності макроорганізму
COVID-19: хто отримає щеплення вакциною Pfizer
Вакцинація від COVID-19: в Україну прибула вакцина...
All news
Keyword : non-small cell lung cancer
Pembrolizumab is first-line treatment for patients with advanced non-small cell lung cancer in both mono and combination regimens
T. 10, № 1-2 (37-38) / Review: 4
Prevalence of
EGFR
gene mutations in Ukrainian patients with locally advanced or metastatic non-small cell lung cancer
Authors: Shparyk Ya.V. Ponomareva O.V. Sokolov V.V. Kobzev O.Y.... T. 10, № 1-2 (37-38) / Review: 18
ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer (review)
Authors: Kolesnik O.P. Shevchenco A.I. Kadzhoian A.V. Kuzmenko V.A.... Т. 8, № 4 (32) 2018 / Review: 2183
The role of targeted therapy in the treatment of patients with EGFR+ mutations of lung cancer (review)
Authors: Kolesnik O.P. Shevchenco A.I. Kadzhoian A.V. Kuzmenko V.A.... Т. 8, № 3 (31) 2018 / Review: 908
Modern approaches to the treatment of inoperable non-small cell lung cancer
Authors: Klimаnоv М.Yu. Sivak L.A. Tarasenko T. Askоlskiy А.В.... №4(24) 2016 / Review: 2761
Erlotinib efficacy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
Author:Toracica Oncologia Italiana Associazione and Pneumo-Cancerologie de Francais Groupe with collaboration in Group Cancer Lung Spanish №7 (3) 2012 / Review: 1
Expression of glicoprotein Pgp-170 by the hemopoietic peripheral blood and bone marrow cells in the CML patients with different response to tyrosine kinase inhibitors therapy
Authors: Perekhrestenko T.P. Gordiyenko A.I. Tretyak N.N. Dyagil I.S.... №5 (1) 2012 / Review: 593